SS-31 for Sciatica: Mitochondrial Repair Evidence Graded Against Tissue and Nerve Layers
What's breaking down if you have Sciatica
- Sciatica is nerve pain along the sciatic nerve — often from disc herniation or stenosis compressing a root.
- The nerve is signaling damage/compression; suppressing pain does not uncompress the nerve.
Why SS-31 (Elamipretide) might help you
- You have Sciatica — breakdown is outpacing repair.
- Therefore for you: If that layer is part of your problem, SS-31 (Elamipretide) is discussed because it targets repair (tissue) — not because it masks pain.
- This article centers SS-31 (Elamipretide); see other sections for bpc-157, tb-500, ara-290 — different layers, same condition.
Why BPC-157 might help you
- You have Sciatica — breakdown is outpacing repair.
- What keeps failing: Poor blood supply at injury, weak collagen organization, slow tissue turnover.
- What BPC-157 is studied to do: Studied for growing new blood vessels (angiogenesis) so repair material reaches damaged tissue.
- Therefore for you: If that layer is part of your problem, BPC-157 is discussed because it targets repair (structure / tissue) — not because it masks pain.
Why TB-500 might help you
- You have Sciatica — breakdown is outpacing repair.
- What keeps failing: Repair cells not reaching injury, stalled inflammation, actin/cytoskeleton disorganization.
- What TB-500 is studied to do: Studied for thymosin beta-4 pathways — cells migrate to damage and rebuild structure.
- Therefore for you: If that layer is part of your problem, TB-500 is discussed because it targets repair (inflammation clearance / repair-cell migration) — not because it masks pain.
Why ARA-290 might help you
- You have Sciatica — breakdown is outpacing repair.
- What keeps failing: Nerve compression, small-fiber loss, neuropathic pain signaling without tissue repair.
- What ARA-290 is studied to do: Studied for nerve repair and small-fiber regeneration in neuropathy models.
- Therefore for you: If that layer is part of your problem, ARA-290 is discussed because it targets repair (nerve / innervation) — not because it masks pain.
How these fit together
Each compound above targets a different degeneration layer. Together they are a stack — not five copies of the same mechanism.
- SS-31 (Elamipretide) → mitochondrial
- BPC-157 → structure / tissue
- TB-500 → inflammation clearance / repair-cell migration
- ARA-290 → nerve / innervation
Primary focus of this slug: SS-31 (Elamipretide). Others are in scope because the same condition breaks down on multiple layers.
What the evidence actually shows
This is a count of what is in this ledger — not a claim about all research worldwide.
- Scientific sources catalogued (PubMed, trials, reviews): 4
- Claims tagged human evidence: 1
- Claims tagged preclinical (animal/lab): 4
- Claims tagged anecdotal: 0
- Reddit posts catalogued: 0
- X posts catalogued: 0
- Other anecdote sources (YouTube, Instagram, etc.): 0
- Total sources in chain: 5
Logic: No social posts catalogued yet — we cannot report what people are saying on Reddit or X from this ledger.
Quantified confidence (this ledger): 0.38 / 1.00 — low–moderate — mostly preclinical
Formula: human claims×0.12 + preclinical×0.04 + anecdote×0.015 + studies (capped). This is not clinical certainty — it measures how much graded evidence is catalogued here.
What scientists say
Low expression of Frataxin might contribute to diabetic ... (source s0)
Rat study showing SS-31 benefits in diabetic neuropathy sciatic model.
Evidence type: Animal or lab work — shows mechanism or early signal, not proof in people.
SS-31 alleviated nociceptive responses and restored mitochondrial function in a headache mouse model (source s1)
Mouse model demonstrating mitochondrial restoration and reduced pain behavior.
Evidence type: Animal or lab work — shows mechanism or early signal, not proof in people.
Stable gastric pentadecapeptide BPC 157 can improve ... (source s26)
Rat sciatic injury study with functional recovery data.
Evidence type: Animal or lab work — shows mechanism or early signal, not proof in people.
ARA 290, a Nonerythropoietic Peptide Engineered from ... (source s32)
Human phase 2 trial results in diabetic neuropathy.
Evidence type: Tagged human evidence in this ledger — check sample size and design.
Peptide components (collapsible embeds)
---
Not medical advice. Counts and quotes are from this article's hash-chained ledger. Anecdote = real reports, not proof. Animal studies ≠ human proof.
Evidence ledger 5 · tier-ranked · API
Model review1 contributions · 1 modelExpand the recursive review layer
/api/articles/ss-31-sciatica/contributionsAsk this article · 7 suggested prompts
Text the build (+14245134626) or WhatsApp — slug|question creates a question node. Paste evidence with ingest slug|q:NODE_ID|your paste.